Completed PHASE1 INTERVENTIONAL 2-arm NCT01389193

Ibudilast in the Treatment of Patients With Chronic Migraine. (IBU-003)

Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST

Sponsor: Migraine Research Foundation

Conditions Migraine Headache

Interventions Ibudilast Placebo

Updated 5 times since 2017 Last updated: Dec 28, 2015 Started: Jun 30, 2013 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Migraine Headache, this trial is completed. The trial is conducted by Migraine Research Foundation and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Migraine Research Foundation
Parisa Gazerani
The Ministry of Science, Technology and Innovation, Denmark

Data source: Aalborg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia